查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
促紅細胞生成素製劑市場規模,份額和趨勢分析報告，按類型(生物製劑,生物仿製藥),產品,應用(癌症,腎臟疾病,神經病學),地區,分部預測2023-2030
市場調查報告書
商品編碼
1233158

促紅細胞生成素製劑市場規模,份額和趨勢分析報告，按類型(生物製劑,生物仿製藥),產品,應用(癌症,腎臟疾病,神經病學),地區,分部預測2023-2030

Erythropoietin Drugs Market Size, Share & Trends Analysis Report By Type (Biologics, Biosimilars) By Product (Erythropoietin, Darbepoetin-alfa), By Application (Cancer, Renal Disease, Neurology), By Region, And Segment Forecasts, 2023 - 2030
出版日期: | 出版商: Grand View Research | 英文 126 Pages | 商品交期: 2-10個工作天內

價格

促紅細胞生成素製劑市場增長和趨勢

Grand View Research, Inc. 的新報告預測全球促紅細胞生成素市場規模將達到 78 億美元，從 2023 年到 2030 年的複合年增長率為 1.5% 增長緩慢可歸因於多項生物專利到期，生物仿製藥的批准和採用增加，價格下降。

例如，PanGen Biotech Inc. 正在開發 Erisa (PDA10)。 這種促紅細胞生成素生物仿製藥正在進行 3 期臨床試驗，以確認其對貧血患者的安全性和有效性。

美國衛生與公眾服務部開展了全國腎臟教育計劃，以提高患者和醫生對慢性腎髒病的認識。 腎臟是成人促紅細胞生成素合成的唯一來源。 隨著 CKD 的進展，腎臟質量減少，導致促紅細胞生成素生成受損和貧血。 因此，提高患者和醫生對疾病和可用 EPO 藥物的認識有望推動市場。

亞太地區,非洲和中東地區對廉價 EPO 藥物的需求不斷增長，促使新進入者進入促紅細胞生成素市場。 因此，一些主要參與者正在努力開發和商業化生物仿製藥。 例如，Novotech (Australia) Pty Limited 有一種 EPO 生物類似藥 efepoetin alfa，正在進行 3 期試驗。

對 EPO 製劑安全性的擔憂促使人們開發出治療貧血的替代療法。 例如，roxudustat (AstraZeneca) 和 daprodustat (GSK) 等 HIF-PH 抑製劑已在日本,中國和韓國獲得批准。 2022 年 3 月，Zydus Lifesciences Ltd. 獲得了印度藥品監管局(DCGI)對 Oxemia(Desidustat)的批准。 它是可注射促紅細胞生成素興奮劑的替代品。 Oxemia 有可能解決未滿足的醫療需求，因為它是印度首個用於治療與慢性腎病相關的貧血的口服藥物。 預計這些替代藥物的批准將對市場增長產生負面影響。

促紅細胞生成素製劑市場報告亮點

  • 按類型劃分，生物製劑將在 2022 年佔據最大的市場份額。 這可能是由於 FDA 批准的 EPO 生物製劑可用於治療癌症特異性貧血和 CKD 患者。
  • 按產品劃分，促紅細胞生成素細分市場在 2022 年主導了 EPO 醫藥市場，原因是獲批產品數量多且促紅細胞生成素的處方率高。
  • 2022 年的 EPO 藥物市場以腎病領域為主。 CKD 的高患病率和 EPO 藥物的高處方率是該細分市場佔據主導地位的主要因素。 根據國家腎臟基金會 (NKF) 的數據，全世界 10% 的人口患有慢性腎髒病 (CKD)。
  • 由於生物仿製藥的審批延遲和市場滲透率低等因素，2022 年全球市場將由北美主導。

內容

第一章調查方法及範圍

  • 市場細分和範圍
    • 區域範圍
  • 調查方法
  • 信息採購
    • 購買的數據庫
    • GVR 內部數據庫
    • 次要信息
    • 初步調查
  • 信息或數據分析
    • 數據分析模型
  • 市場製定和驗證
  • 模型詳細信息
    • 商品流分析(模型 1)
      • 方法 1:商品流方法
  • 調查假設
  • 二級信息列表
  • 縮寫列表
  • 目的

第 2 章執行摘要

  • 市場概況
  • 片段快照
  • 競爭格局快照

第 3 章促紅細胞生成素藥物市場變量,趨勢和範圍

  • 市場系列展望
    • 母公司市場展望
  • 類型滲透和增長前景圖，2022 年
  • 市場動態
    • 市場驅動因素分析
      • 慢性病發病率增加
      • 標籤外使用紅細胞生成刺激劑 (ESA)
    • 市場製約因素分析
      • 品牌藥的專利到期
  • 市場分析工具
    • 行業分析:波特五力模型
      • 新進入者的威脅:中等
      • 買方的議價能力:正常
      • 競爭對手之間的敵意:高
      • 替代品威脅:高
      • 供應商的議價能力:低
    • 行業分析:Pestel
      • 政治與法律
      • 經濟的
      • 技術
  • 管道分析

第 4 章促紅細胞生成素市場:細分分析，按類型，2018-2030(百萬美元)

  • 促紅細胞生成素製劑市場:按類型的變化分析
    • 生物製劑
    • 生物仿製藥

第 5 章促紅細胞生成素藥物市場:細分分析，副產品，2018-2030(百萬美元)

  • 促紅細胞生成素製劑市場:產品差異分析
    • 促紅細胞生成素
    • 阿爾法達貝泊汀

第 6 章促紅細胞生成素藥物市場:細分分析，按應用，2018-2030(百萬美元)

  • 促紅細胞生成素製劑市場:應用的變化分析
    • 癌症
    • 腎臟疾病
    • 神經學
    • 其他

第 7 章促紅細胞生成素產品市場:按類型,產品和應用分列的區域估計和趨勢分析

  • 北美
    • SWOT 分析
    • 美國
      • 主要國家動態
      • 目標疾病的患病率
      • 競爭場景
      • 監管框架
      • 贖回場景
    • 加拿大
      • 主要國家動態
      • 目標疾病的患病率
      • 競爭場景
      • 監管框架
      • 贖回場景
  • 歐洲
    • SWOT 分析:
    • 德國
      • 主要國家動態
      • 目標疾病的患病率
      • 競爭場景
      • 監管框架
      • 贖回場景
    • 英國
      • 主要國家動態
      • 目標疾病的患病率
      • 競爭場景
      • 監管框架
      • 贖回場景
    • 法國
      • 主要國家動態
      • 目標疾病的患病率
      • 競爭場景
      • 監管框架
      • 贖回場景
    • 意大利
      • 主要國家動態
      • 目標疾病的患病率
      • 競爭場景
      • 監管框架
      • 贖回場景
    • 西班牙
      • 主要國家動態
      • 目標疾病的患病率
      • 競爭場景
      • 監管框架
      • 贖回場景
    • 丹麥
      • 主要國家動態
      • 目標疾病的患病率
      • 競爭場景
      • 監管框架
      • 贖回場景
    • 瑞典
      • 主要國家動態
      • 目標疾病的患病率
      • 競爭場景
      • 監管框架
      • 贖回場景
    • 挪威
      • 主要國家動態
      • 目標疾病的患病率
      • 競爭場景
      • 監管框架
      • 贖回場景
  • 亞太地區
    • SWOT 分析
    • 日本
      • 主要國家動態
      • 目標疾病的患病率
      • 競爭場景
      • 監管框架
      • 贖回場景
    • 中國
      • 主要國家動態
      • 目標疾病的患病率
      • 競爭場景
      • 監管框架
      • 贖回場景
    • 印度
      • 主要國家動態
      • 目標疾病的患病率
      • 競爭場景
      • 監管框架
      • 贖回場景
    • 澳大利亞
      • 主要國家動態
      • 目標疾病的患病率
      • 競爭場景
      • 監管框架和贖回方案
    • 泰國
      • 主要國家動態
      • 目標疾病的患病率
      • 競爭場景
      • 監管框架和贖回方案
    • 韓國
      • 主要國家動態
      • 目標疾病的患病率
      • 競爭場景
      • 監管框架和贖回方案
  • 拉丁美洲
    • SWOT 分析:
    • 巴西
      • 主要國家動態
      • 目標疾病的患病率
      • 競爭場景
      • 監管框架
      • 贖回場景
    • 墨西哥
      • 主要國家動態
      • 目標疾病的患病率
      • 競爭場景
      • 監管框架
      • 贖回場景
    • 阿根廷
      • 主要國家動態
      • 目標疾病的患病率
      • 競爭場景
      • 監管框架
      • 贖回場景
  • 中東和非洲 (MEA)
    • SWOT 分析:
    • 南非
      • 主要國家動態
      • 目標疾病的患病率
      • 競爭場景
      • 監管框架
      • 贖回場景
    • 沙特阿拉伯
      • 主要國家動態
      • 目標疾病的患病率
      • 競爭場景
      • 監管框架
      • 贖回場景
    • 阿拉伯聯合酋長國
      • 主要國家動態
      • 目標疾病的患病率
      • 競爭場景
      • 監管框架
      • 贖回場景
    • 科威特
      • 主要國家動態
      • 目標疾病的患病率
      • 競爭場景
      • 監管框架
      • 贖回場景

第八章競爭格局

  • 主要市場參與者的近期發展和影響分析
    • 新產品發布
    • 併購
    • 許可協議
    • 會議和活動
  • 公司分類
    • 創新者
    • 市場領導者
  • 供應商概況
    • 主要分銷商和渠道合作夥伴列表
    • 主要客戶
  • 上市公司
    • 2022 年主要參與者的市場份額分析
    • 公司市場分析
    • 熱圖分析
    • 競爭儀錶盤分析
      • 市場差異化因素
  • 私人公司
    • 主要初創公司名單
    • 本地網絡地圖
  • 公司簡介
    • 強生服務公司
      • 公司簡介
      • 財務業績
      • 產品基準
      • 戰略舉措
    • 諾華公司
      • 公司簡介
      • 財務業績
      • 產品基準
      • 戰略舉措
    • 梯瓦製藥工業有限公司
      • 公司簡介
      • 財務業績
      • 產品基準
      • 戰略舉措
    • 安進公司
      • 公司簡介
      • 財務業績
      • 產品基準
      • 戰略舉措
    • F. Hoffmann-La Roche Ltd.
      • 公司簡介
      • 財務業績
      • 產品基準
      • 戰略舉措
    • LG 化學
      • 公司簡介
      • 財務業績
      • 產品基準
      • 戰略舉措
    • 比奧康
      • 公司簡介
      • 財務業績
      • 產品基準
      • 戰略舉措
    • Intas Pharmaceuticals Ltd.
      • 公司簡介
      • 財務業績
      • 產品基準
      • 戰略舉措
    • 太陽製藥工業有限公司
      • 公司簡介
      • 財務業績
      • 產品基準
      • 戰略舉措
    • 雷迪博士實驗室有限公司
      • 公司簡介
      • 產品基準
      • 戰略舉措
Product Code: GVR-1-68038-861-9

Erythropoietin Drugs Market Growth & Trends:

The global erythropoietin drugs market size is expected to reach USD 7.8 billion expanding at a CAGR of 1.5% from 2023 to 2030, according to a new report by Grand View Research, Inc., The slow growth can be attributed to the patent expiry of multiple biologics, increasing approval and penetration of biosimilars, and declining prices. For instance, PanGen Biotech Inc. is developing Erisa (PDA10). This erythropoietin biosimilar drug is under phase 3 clinical trial to check the safety and efficacy of the drug in patients with anemia.

The U.S. Department of Health and Human Services runs the National Kidney Disease Education Program to raise awareness about chronic kidney disease conditions among patients and physicians. The kidney is the sole source of erythropoietin synthesis in adults. In progressive CKD, the kidney mass decreases, which results in the impairment of erythropoietin production, thereby causing anemia. Thus, the rising awareness about the disease and its available EPO medicines among patients and physicians is anticipated to drive the market.

Increasing demand for cheaper EPO drugs in Asia Pacific, Africa, and the Middle East has triggered the entry of new players in the erythropoietin drugs market. Thus, some of the key players are engaged in the development and commercialization of biosimilars. For instance, Novotech (Australia) Pty Limited has an EPO biosimilar, Efepoetin alfa in phase 3 trials.

Safety concerns with EPO agents have encouraged the development of alternative treatments for anemia. For instance, HIF-PH inhibitors such as roxudustat (AstraZeneca) and daprodustat (GSK) have been approved in Japan, China, and South Korea amongst others. In March 2022, Zydus Lifesciences Ltd. received approval for Oxemia (Desidustat) from the Drug Controller General of India (DCGI). It is an alternative to injectable erythropoietin-stimulating agents. Oxemia is a potential product, a first-of-its-kind oral treatment in India, for anemia associated with chronic kidney diseases, thereby solving unmet needs. The approval of these alternative drugs is expected to negatively impact market growth.

Erythropoietin Drugs Market Report Highlights:

  • By type, the biologics segment accounted for the largest share of the market in 2022. This can be attributed to the availability of FDA-approved EPO biologics for the treatment of cancer-induced anemia and CKD patients.
  • Based on product, the erythropoietin segment dominated the EPO drugs market in 2022 owing to the higher number of approved products and higher prescription rate of erythropoietin.
  • The renal diseases segment dominated the EPO drugs market in 2022. The high prevalence of CKD and the high prescription rate of EPO drugs are major factors contributing to the dominance of this segment. According to the National Kidney Foundation (NKF), 10% of the total population is affected by chronic kidney disease (CKD) worldwide.
  • North America dominated the global market in 2022 owing to factors such as late approval and lower penetration of biosimilars in the market

Table of Contents

Chapter 1 Methodology and Scope

  • 1.1 Market Segmentation and Scope
    • 1.1.1 Regional scope
    • 1.1.2 Estimates and forecast timeline
  • 1.2 Research Methodology
  • 1.3 Information Procurement
    • 1.3.1 Purchased database
    • 1.3.2 GVR's internal database
    • 1.3.3 Secondary sources
    • 1.3.4 Primary research
  • 1.4 Information or Data Analysis
    • 1.4.1 Data analysis models
  • 1.5 Market Formulation & Validation
  • 1.6 Model Details
    • 1.6.1 Commodity Flow Analysis (Model 1)
      • 1.6.1.1 Approach 1: Commodity Flow Approach
  • 1.7 Research Assumptions
  • 1.8 List of Secondary Sources
  • 1.9 List of Abbreviations
  • 1.10 Objectives
    • 1.10.1 Objective 1
    • 1.10.2 Objective 2
    • 1.10.3 Objective 3
    • 1.10.4 Objective 4

Chapter 2 Executive Summary

  • 2.1 Market Snapshot
  • 2.2 Segment Snapshot
  • 2.3 Competitive Landscape Snapshot

Chapter 3 Erythropoietin Drugs Market Variables, Trends, and Scope

  • 3.1 Market Lineage Outlook
    • 3.1.1 Parent market outlook
  • 3.2 Penetration and Growth Prospect Mapping for Type, 2022
  • 3.3 Market Dynamics
    • 3.3.1 Market Driver Analysis
      • 3.3.1.1 Increasing incidence of chronic diseases
      • 3.3.1.2 Off-label use of Erythropoiesis stimulating agents (ESAs)
    • 3.3.2 Market Restraint Analysis
      • 3.3.2.1 Patent expiration of branded drugs
  • 3.4 Market Analysis Tools
    • 3.4.1 Industry Analysis: Porter's Five Forces
      • 3.4.1.1 Threat of new entrants: Moderate
      • 3.4.1.2 Bargaining power of buyers: Moderate
      • 3.4.1.3 Competitive rivalry: High
      • 3.4.1.4 Threat of substitutes: High
      • 3.4.1.5 Bargaining power of suppliers: Low
    • 3.4.2 Industry Analysis: PESTEL
      • 3.4.2.1 Political & Legal
      • 3.4.2.2 Economical
      • 3.4.2.3 Technological
  • 3.5 Pipeline Analysis

Chapter 4 Erythropoietin Drugs Market: Segment Analysis, by Type, 2018 - 2030 (USD Million)

  • 4.1 Erythropoietin Drugs Market: Type Movement Analysis
    • 4.1.1 Biologics
      • 4.1.1.1 Biologics Market Estimates and Forecast, 2018 - 2030 (USD Million)
    • 4.1.2 Biosimilars
      • 4.1.2.1 Biosimilars Market Estimates and Forecast, 2018 - 2030 (USD Million)

Chapter 5 Erythropoietin Drugs Market: Segment Analysis, by Product, 2018 - 2030 (USD Million)

  • 5.1 Erythropoietin Drugs Market: Product Movement Analysis
    • 5.1.1 Erythropoietin
      • 5.1.1.1 Erythropoietin Market Estimates and Forecast, 2018 - 2030 (USD Million)
    • 5.1.2 Darbepoetin-alfa
      • 5.1.2.1 Darbepoetin Market Estimates and Forecast, 2018 - 20302018 - 2030 (USD Million)

Chapter 6 Erythropoietin Drugs Market: Segment Analysis, by Application, 2018 - 2030 (USD Million)

  • 6.1 Erythropoietin Drugs Market: Application Movement Analysis
    • 6.1.1 Cancer
      • 6.1.1.1 Cancer Market Estimates and Forecast, 2018 - 20302018 - 2030 (USD Million)
    • 6.1.2 Renal Diseases
      • 6.1.2.1 Renal Diseases Market Estimates and Forecast, 2018 - 2030 (USD Million)
    • 6.1.3 Neurology
      • 6.1.3.1 Neurology Market Estimates and Forecast, 2018 - 2030 (USD Million)
    • 6.1.4 Others
      • 6.1.4.1 Others Market Estimates and Forecast, 2018 - 2030 (USD Million)

Chapter 7 Erythropoietin Drugs Market: Regional Estimates and Trend Analysis, by Type, Product, & Application

  • 7.1 North America
    • 7.1.1 SWOT Analysis
      • 7.1.1.1 North America Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.1.2 U.S.
      • 7.1.2.1 Key Country Dynamics
      • 7.1.2.2 Target Disease Prevalence
      • 7.1.2.3 Competitive Scenario
      • 7.1.2.4 Regulatory Framework
      • 7.1.2.5 Reimbursement Scenario
      • 7.1.2.6 U.S. Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.1.3 Canada
      • 7.1.3.1 Key Country Dynamics
      • 7.1.3.2 Target Disease Prevalence
      • 7.1.3.3 Competitive Scenario
      • 7.1.3.4 Regulatory Framework
      • 7.1.3.5 Reimbursement Scenario
      • 7.1.3.6 Canada Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.2 Europe
    • 7.2.1 SWOT Analysis:
      • 7.2.1.1 Europe Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.2 Germany
      • 7.2.2.1 Key Country Dynamics
      • 7.2.2.2 Target Disease Prevalence
      • 7.2.2.3 Competitive Scenario
      • 7.2.2.4 Regulatory Framework
      • 7.2.2.5 Reimbursement Scenario
      • 7.2.2.6 Germany Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.3 UK
      • 7.2.3.1 Key Country Dynamics
      • 7.2.3.2 Target Disease Prevalence
      • 7.2.3.3 Competitive Scenario
      • 7.2.3.4 Regulatory Framework
      • 7.2.3.5 Reimbursement Scenario
      • 7.2.3.6 UK Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.4 France
      • 7.2.4.1 Key Country Dynamics
      • 7.2.4.2 Target Disease Prevalence
      • 7.2.4.3 Competitive Scenario
      • 7.2.4.4 Regulatory Framework
      • 7.2.4.5 Reimbursement Scenario
      • 7.2.4.6 France Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.5 Italy
      • 7.2.5.1 Key Country Dynamics
      • 7.2.5.2 Target Disease Prevalence
      • 7.2.5.3 Competitive Scenario
      • 7.2.5.4 Regulatory Framework
      • 7.2.5.5 Reimbursement Scenario
      • 7.2.5.6 Italy Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.6 Spain
      • 7.2.6.1 Key Country Dynamics
      • 7.2.6.2 Target Disease Prevalence
      • 7.2.6.3 Competitive Scenario
      • 7.2.6.4 Regulatory Framework
      • 7.2.6.5 Reimbursement Scenario
      • 7.2.6.6 Spain Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.7 Denmark
      • 7.2.7.1 Key Country Dynamics
      • 7.2.7.2 Target Disease Prevalence
      • 7.2.7.3 Competitive Scenario
      • 7.2.7.4 Regulatory Framework
      • 7.2.7.5 Reimbursement Scenario
      • 7.2.7.6 Denmark Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.8 Sweden
      • 7.2.8.1 Key Country Dynamics
      • 7.2.8.2 Target Disease Prevalence
      • 7.2.8.3 Competitive Scenario
      • 7.2.8.4 Regulatory Framework
      • 7.2.8.5 Reimbursement Scenario
      • 7.2.8.6 Sweden Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.9 Norway
      • 7.2.9.1 Key Country Dynamics
      • 7.2.9.2 Target Disease Prevalence
      • 7.2.9.3 Competitive Scenario
      • 7.2.9.4 Regulatory Framework
      • 7.2.9.5 Reimbursement Scenario
      • 7.2.9.6 Norway Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 7.2.9.7 Rest of Europe Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.3 Asia Pacific
    • 7.3.1 SWOT Analysis:
      • 7.3.1.1 Asia Pacific Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.2 Japan
      • 7.3.2.1 Key Country Dynamics
      • 7.3.2.2 Target Disease Prevalence
      • 7.3.2.3 Competitive Scenario
      • 7.3.2.4 Regulatory Framework
      • 7.3.2.5 Reimbursement Scenario
      • 7.3.2.6 Japan Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.3 China
      • 7.3.3.1 Key Country Dynamics
      • 7.3.3.2 Target Disease Prevalence
      • 7.3.3.3 Competitive Scenario
      • 7.3.3.4 Regulatory Framework
      • 7.3.3.5 Reimbursement Scenario
      • 7.3.3.6 China Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.4 India
      • 7.3.4.1 Key Country Dynamics
      • 7.3.4.2 Target Disease Prevalence
      • 7.3.4.3 Competitive Scenario
      • 7.3.4.4 Regulatory Framework
      • 7.3.4.5 Reimbursement Scenario
      • 7.3.4.6 India Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.5 Australia
      • 7.3.5.1 Key Country Dynamics
      • 7.3.5.2 Target Disease Prevalence
      • 7.3.5.3 Competitive Scenario
      • 7.3.5.4 Regulatory Framework & Reimbursement Scenario
      • 7.3.5.5 Australia Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.6 Thailand
      • 7.3.6.1 Key Country Dynamics
      • 7.3.6.2 Target Disease Prevalence
      • 7.3.6.3 Competitive Scenario
      • 7.3.6.4 Regulatory Framework & Reimbursement Scenario
      • 7.3.6.5 Thailand Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.7 South Korea
      • 7.3.7.1 Key Country Dynamics
      • 7.3.7.2 Target Disease Prevalence
      • 7.3.7.3 Competitive Scenario
      • 7.3.7.4 Regulatory Framework & Reimbursement Scenario
      • 7.3.7.5 South Korea Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 7.3.7.6 Rest of Asia Pacific Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4 Latin America
    • 7.4.1 SWOT Analysis:
      • 7.4.1.1 Latin America Erythropoietin Drugs market estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.4.2 Brazil
      • 7.4.2.1 Key Country Dynamics
      • 7.4.2.2 Target Disease Prevalence
      • 7.4.2.3 Competitive Scenario
      • 7.4.2.4 Regulatory Framework
      • 7.4.2.5 Reimbursement Scenario
      • 7.4.2.6 Brazil Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.3 Mexico
      • 7.4.3.1 Key Country Dynamics
      • 7.4.3.2 Target Disease Prevalence
      • 7.4.3.3 Competitive Scenario
      • 7.4.3.4 Regulatory Framework
      • 7.4.3.5 Reimbursement Scenario
      • 7.4.3.6 Mexico Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.4 Argentina
      • 7.4.4.1 Key Country Dynamics
      • 7.4.4.2 Target Disease Prevalence
      • 7.4.4.3 Competitive Scenario
      • 7.4.4.4 Regulatory Framework
      • 7.4.4.5 Reimbursement Scenario
      • 7.4.4.6 Argentina Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 7.4.4.7 Rest of Latin America Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5 Middle East & Africa (MEA)
    • 7.5.1 SWOT Analysis:
      • 7.5.1.1 Middle East & Africa Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.2 South Africa
      • 7.5.2.1 Key Country Dynamics
      • 7.5.2.2 Target Disease Prevalence
      • 7.5.2.3 Competitive Scenario
      • 7.5.2.4 Regulatory Framework
      • 7.5.2.5 Reimbursement Scenario
      • 7.5.2.6 South Africa Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.3 Saudi Arabia
      • 7.5.3.1 Key Country Dynamics
      • 7.5.3.2 Target Disease Prevalence
      • 7.5.3.3 Competitive Scenario
      • 7.5.3.4 Regulatory Framework
      • 7.5.3.5 Reimbursement Scenario
      • 7.5.3.6 Saudi Arabia Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.4 UAE
      • 7.5.4.1 Key Country Dynamics
      • 7.5.4.2 Target Disease Prevalence
      • 7.5.4.3 Competitive Scenario
      • 7.5.4.4 Regulatory Framework
      • 7.5.4.5 Reimbursement Scenario
      • 7.5.4.6 UAE Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.5 Kuwait
      • 7.5.5.1 Key Country Dynamics
      • 7.5.5.2 Target Disease Prevalence
      • 7.5.5.3 Competitive Scenario
      • 7.5.5.4 Regulatory Framework
      • 7.5.5.5 Reimbursement Scenario
      • 7.5.5.6 Kuwait Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 7.5.5.7 Rest of MEA Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8 Competitive Landscape

  • 8.1 Recent Developments & Impact Analysis, by Key Market Participants
    • 8.1.1 New Product Launch
    • 8.1.2 Merger and Acquisition
    • 8.1.3 Licensing Agreements
    • 8.1.4 Conferences and Campaigns
  • 8.2 Company Categorization
    • 8.2.1 Innovators
    • 8.2.2 Market Leaders
  • 8.3 Vendor Landscape
    • 8.3.1 List of Key Distributors and Channel Partners
    • 8.3.2 Key Customers
  • 8.4 Public Companies
    • 8.4.1 Key Company Market Share Analysis, 2022
    • 8.4.2 Company Market Position Analysis
    • 8.4.3 Heat Map Analysis
    • 8.4.4 Competitive Dashboard Analysis
      • 8.4.4.1 Market Differentiators
  • 8.5 Private Companies
    • 8.5.1 List of Key Emerging Companies
    • 8.5.2 Regional Network Map
  • 8.6 Company Profiles
    • 8.6.1. Johnson & Johnson Services, Inc.
      • 8.6.1.1 Company Overview
      • 8.6.1.2 Financial Performance
      • 8.6.1.3 Product Benchmarking
      • 8.6.1.4 Strategic Initiatives
    • 8.6.2 Novartis AG
      • 8.6.2.1 Company Overview
      • 8.6.2.2 Financial Performance
      • 8.6.2.3 Product Benchmarking
      • 8.6.2.4 Strategic Initiatives
    • 8.6.3 Teva Pharmaceutical Industries Ltd.
      • 8.6.3.1 Company Overview
      • 8.6.3.2 Financial Performance
      • 8.6.3.3 Product Benchmarking
      • 8.6.3.4 Strategic Initiatives
    • 8.6.4 Amgen, Inc.
      • 8.6.4.1 Company Overview
      • 8.6.4.2 Financial Performance
      • 8.6.4.3 Product Benchmarking
      • 8.6.4.4 Strategic Initiatives
    • 8.6.5 F. Hoffmann-La Roche Ltd.
      • 8.6.5.1 Company Overview
      • 8.6.5.2 Financial Performance
      • 8.6.5.3 Product Benchmarking
      • 8.6.5.4 Strategic Initiatives
    • 8.6.6 LG Chem
      • 8.6.6.1 Company Overview
      • 8.6.6.2 Financial Performance
      • 8.6.6.3 Product Benchmarking
      • 8.6.6.4 Strategic Initiatives
    • 8.6.7 Biocon
      • 8.6.7.1 Company Overview
      • 8.6.7.2 Financial Performance
      • 8.6.7.3 Product Benchmarking
      • 8.6.7.4 Strategic Initiatives
    • 8.6.8 Intas Pharmaceuticals Ltd.
      • 8.6.8.1 Company Overview
      • 8.6.8.2 Financial Performance
      • 8.6.8.3 Product Benchmarking
      • 8.6.8.4 Strategic Initiatives
    • 8.6.9 Sun Pharmaceutical Industries Ltd.
      • 8.6.8.1 Company Overview
      • 8.6.9.2 Financial Performance
      • 8.6.9.3 Product Benchmarking
      • 8.6.9.4 Strategic Initiatives
    • 8.6.10 Dr. Reddy's Laboratories Ltd
      • 8.6.10.1 Company Overview
      • 8.6.10.2 Product Benchmarking
      • 8.6.10.3 Strategic Initiatives

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 Regulatory Framework
  • Table 4 Global Erythropoietin Drugs Market, By Region, 2018 - 2030 (USD Million)
  • Table 5 Global Erythropoietin Drugs Market, By Type, 2018 - 2030 (USD Million)
  • Table 6 Global Erythropoietin Drugs Market, By Product, 2018 - 2030 (USD Million)
  • Table 7 Global Erythropoietin Drugs Market, By Application, 2018 - 2030 (USD Million)
  • Table 8 North America Erythropoietin Drugs Market, By Country, 2018 - 2030 (USD Million)
  • Table 9 North America Erythropoietin Drugs Market, By Type, 2018 - 2030 (USD Million)
  • Table 10 North America Erythropoietin Drugs Market, By Product, 2018 - 2030 (USD Million)
  • Table 11 North America Erythropoietin Drugs Market, By Application, 2018 - 2030 (USD Million)
  • Table 12 U.S. Erythropoietin Drugs Market, By Type, 2018 - 2030 (USD Million)
  • Table 13 U.S. Erythropoietin Drugs Market, By Product, 2018 - 2030 (USD Million)
  • Table 14 U.S. Erythropoietin Drugs Market, By Application, 2018 - 2030 (USD Million)
  • Table 15 Canada Erythropoietin Drugs Market, By Type, 2018 - 2030 (USD Million)
  • Table 16 Canada Erythropoietin Drugs Market, By Product, 2018 - 2030 (USD Million)
  • Table 17 Canada Erythropoietin Drugs Market, By Application, 2018 - 2030 (USD Million)
  • Table 18 Europe Erythropoietin Drugs Market, By Country, 2018 - 2030 (USD Million)
  • Table 19 Europe Erythropoietin Drugs Market, By Type, 2018 - 2030 (USD Million)
  • Table 20 Europe Erythropoietin Drugs Market, By Product, 2018 - 2030 (USD Million)
  • Table 21 Europe Erythropoietin Drugs Market, By Application, 2018 - 2030 (USD Million)
  • Table 22 Germany Erythropoietin Drugs Market, By Type, 2018 - 2030 (USD Million)
  • Table 23 Germany Erythropoietin Drugs Market, By Product, 2018 - 2030 (USD Million)
  • Table 24 Germany Erythropoietin Drugs Market, By Application, 2018 - 2030 (USD Million)
  • Table 25 U.K. Erythropoietin Drugs Market, By Type, 2018 - 2030 (USD Million)
  • Table 26 U.K. Erythropoietin Drugs Market, By Product, 2018 - 2030 (USD Million)
  • Table 27 U.K. Erythropoietin Drugs Market, By Application, 2018 - 2030 (USD Million)
  • Table 28 France Erythropoietin Drugs Market, By Type, 2018 - 2030 (USD Million)
  • Table 29 France Erythropoietin Drugs Market, By Product, 2018 - 2030 (USD Million)
  • Table 30 France Erythropoietin Drugs Market, By Application, 2018 - 2030 (USD Million)
  • Table 31 Italy Erythropoietin Drugs Market, By Type, 2018 - 2030 (USD Million)
  • Table 32 Italy Erythropoietin Drugs Market, By Product, 2018 - 2030 (USD Million)
  • Table 33 Italy Erythropoietin Drugs Market, By Application, 2018 - 2030 (USD Million)
  • Table 34 Spain Erythropoietin Drugs Market, By Type, 2018 - 2030 (USD Million)
  • Table 35 Spain Erythropoietin Drugs Market, By Product, 2018 - 2030 (USD Million)
  • Table 36 Spain Erythropoietin Drugs Market, By Application, 2018 - 2030 (USD Million)
  • Table 37 Denmark Erythropoietin Drugs Market, By Type, 2018 - 2030 (USD Million)
  • Table 38 Denmark Erythropoietin Drugs Market, By Product, 2018 - 2030 (USD Million)
  • Table 39 Denmark Erythropoietin Drugs Market, By Application, 2018 - 2030 (USD Million)
  • Table 40 Sweden Erythropoietin Drugs Market, By Type, 2018 - 2030 (USD Million)
  • Table 41 Sweden Erythropoietin Drugs Market, By Product, 2018 - 2030 (USD Million)
  • Table 42 Sweden Erythropoietin Drugs Market, By Application, 2018 - 2030 (USD Million)
  • Table 43 Norway Erythropoietin Drugs Market, By Type, 2018 - 2030 (USD Million)
  • Table 44 Norway Erythropoietin Drugs Market, By Product, 2018 - 2030 (USD Million)
  • Table 45 Norway Erythropoietin Drugs Market, By Application, 2018 - 2030 (USD Million)
  • Table 46 Asia Pacific Erythropoietin Drugs Market, By Country, 2018 - 2030 (USD Million)
  • Table 47 Asia Pacific Erythropoietin Drugs Market, By Type, 2018 - 2030 (USD Million)
  • Table 48 Asia Pacific Erythropoietin Drugs Market, By Product, 2018 - 2030 (USD Million)
  • Table 49 Asia Pacific Erythropoietin Drugs Market, By Application, 2018 - 2030 (USD Million)
  • Table 50 Japan Erythropoietin Drugs Market, By Type, 2018 - 2030 (USD Million)
  • Table 51 Japan Erythropoietin Drugs Market, By Product, 2018 - 2030 (USD Million)
  • Table 52 Japan Erythropoietin Drugs Market, By Application, 2018 - 2030 (USD Million)
  • Table 53 China Erythropoietin Drugs Market, By Type, 2018 - 2030 (USD Million)
  • Table 54 China Erythropoietin Drugs Market, By Product, 2018 - 2030 (USD Million)
  • Table 55 China Erythropoietin Drugs Market, By Application, 2018 - 2030 (USD Million)
  • Table 56 India Erythropoietin Drugs Market, By Type, 2018 - 2030 (USD Million)
  • Table 57 India Erythropoietin Drugs Market, By Product, 2018 - 2030 (USD Million)
  • Table 58 India Erythropoietin Drugs Market, By Application, 2018 - 2030 (USD Million)
  • Table 59 South Korea Erythropoietin Drugs Market, By Type, 2018 - 2030 (USD Million)
  • Table 60 South Korea Erythropoietin Drugs Market, By Product, 2018 - 2030 (USD Million)
  • Table 61 South Korea Erythropoietin Drugs Market, By Application, 2018 - 2030 (USD Million)
  • Table 62 Australia Erythropoietin Drugs Market, By Type, 2018 - 2030 (USD Million)
  • Table 63 Australia Erythropoietin Drugs Market, By Product, 2018 - 2030 (USD Million)
  • Table 64 Australia Erythropoietin Drugs Market, By Application, 2018 - 2030 (USD Million)
  • Table 65 Thailand Erythropoietin Drugs Market, By Type, 2018 - 2030 (USD Million)
  • Table 66 Thailand Erythropoietin Drugs Market, By Product, 2018 - 2030 (USD Million)
  • Table 67 Thailand Erythropoietin Drugs Market, By Application, 2018 - 2030 (USD Million)
  • Table 68 Latin America Erythropoietin Drugs Market, By Country, 2018 - 2030 (USD Million)
  • Table 69 Latin America Erythropoietin Drugs Market, By Type, 2018 - 2030 (USD Million)
  • Table 70 Latin America Erythropoietin Drugs Market, By Product, 2018 - 2030 (USD Million)
  • Table 71 Latin America Erythropoietin Drugs Market, By Application, 2018 - 2030 (USD Million)
  • Table 72 Brazil Erythropoietin Drugs Market, By Type, 2018 - 2030 (USD Million)
  • Table 73 Brazil Erythropoietin Drugs Market, By Product, 2018 - 2030 (USD Million)
  • Table 74 Brazil Erythropoietin Drugs Market, By Application, 2018 - 2030 (USD Million)
  • Table 75 Mexico Erythropoietin Drugs Market, By Type, 2018 - 2030 (USD Million)
  • Table 76 Mexico Erythropoietin Drugs Market, By Product, 2018 - 2030 (USD Million)
  • Table 77 Mexico Erythropoietin Drugs Market, By Application, 2018 - 2030 (USD Million)
  • Table 78 Argentina Erythropoietin Drugs Market, By Type, 2018 - 2030 (USD Million)
  • Table 79 Argentina Erythropoietin Drugs Market, By Product, 2018 - 2030 (USD Million)
  • Table 80 Argentina Erythropoietin Drugs Market, By Application, 2018 - 2030 (USD Million)
  • Table 81 Middle East & Africa Erythropoietin Drugs Market, By Country, 2018 - 2030 (USD Million)
  • Table 82 Middle East & Africa Erythropoietin Drugs Market, By Type, 2018 - 2030 (USD Million)
  • Table 83 Middle East & Africa Erythropoietin Drugs Market, By Product, 2018 - 2030 (USD Million)
  • Table 84 Middle East & Africa Erythropoietin Drugs Market, By Application, 2018 - 2030 (USD Million)
  • Table 85 Saudi Arabia Erythropoietin Drugs Market, By Type, 2018 - 2030 (USD Million)
  • Table 86 Saudi Arabia Erythropoietin Drugs Market, By Product, 2018 - 2030 (USD Million)
  • Table 87 Saudi Arabia Erythropoietin Drugs Market, By Application, 2018 - 2030 (USD Million)
  • Table 88 South Africa Erythropoietin Drugs Market, By Type, 2018 - 2030 (USD Million)
  • Table 89 South Africa Erythropoietin Drugs Market, By Product, 2018 - 2030 (USD Million)
  • Table 90 South Africa Erythropoietin Drugs Market, By Application, 2018 - 2030 (USD Million)
  • Table 91 UAE Erythropoietin Drugs Market, By Type, 2018 - 2030 (USD Million)
  • Table 92 UAE Erythropoietin Drugs Market, By Product, 2018 - 2030 (USD Million)
  • Table 93 UAE Erythropoietin Drugs Market, By Application, 2018 - 2030 (USD Million)
  • Table 94 Kuwait Erythropoietin Drugs Market, By Type, 2018 - 2030 (USD Million)
  • Table 95 Kuwait Erythropoietin Drugs Market, By Product, 2018 - 2030 (USD Million)
  • Table 96 Kuwait Erythropoietin Drugs Market, By Application, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Erythropoietin drugs market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Information procurement
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value - chain - based sizing & forecasting
  • Fig. 7 QFD modeling for market share assessment
  • Fig. 8 Market formulation & validation
  • Fig. 9 Market snapshot
  • Fig. 10 Segment snapshot (By type, by product, and by application)
  • Fig. 11 Competitive landscape snapshot
  • Fig. 12 Penetration & growth prospect mapping for type, 2022
  • Fig. 13 Market driver relevance analysis (Current & future impact)
  • Fig. 14 Market restraint relevance analysis (Current & future impact)
  • Fig. 15 Erythropoietin drugs market: Type outlook and key takeaways
  • Fig. 16 Erythropoietin drugs market: Type movement analysis
  • Fig. 17 Biologics market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 18 Biosimilars market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 19 Erythropoietin drugs market: Product outlook and key takeaways
  • Fig. 20 Erythropoietin drugs market: Product movement analysis
  • Fig. 21 Erythropoietin market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 22 Darbepoetin - alfa market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 23 Erythropoietin drugs market: Application outlook and key takeaways
  • Fig. 24 Erythropoietin drugs market: Application movement analysis
  • Fig. 25 Cancer market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 26 Renal diseases market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 27 Neurology market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 28 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 29 Regional Marketplace: Key Takeaways
  • Fig. 30 North America: SWOT analysis
  • Fig. 31 North America Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 32 U.S. Key Country Dynamics
  • Fig. 33 U.S. Target Disease Prevalence
  • Fig. 34 U.S. Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 35 Canada Key Country Dynamics
  • Fig. 36 Canada Target Disease Prevalence
  • Fig. 37 Canada Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 38 Europe: SWOT analysis
  • Fig. 39 Europe Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 40 Germany Key Country Dynamics
  • Fig. 41 Germany Target Disease Prevalence
  • Fig. 42 Germany Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 43 U.K. Key Country Dynamics
  • Fig. 44 U.K. Target Disease Prevalence
  • Fig. 45 U.K. Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 46 France Key Country Dynamics
  • Fig. 47 France Target Disease Prevalence
  • Fig. 48 France Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 49 Italy Key Country Dynamics
  • Fig. 50 Italy Target Disease Prevalence
  • Fig. 51 Italy Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 52 Spain Key Country Dynamics
  • Fig. 53 Spain Target Disease Prevalence
  • Fig. 54 Spain Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 55 Denmark Key Country Dynamics
  • Fig. 56 Denmark Target Disease Prevalence
  • Fig. 57 Denmark Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 58 Sweden Key Country Dynamics
  • Fig. 59 Sweden Target Disease Prevalence
  • Fig. 60 Sweden Erythropoietin Drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 61 Norway Key Country Dynamics
  • Fig. 62 Norway Target Disease Prevalence
  • Fig. 63 Norway Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 64 Rest of Europe Erythropoietin Drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 65 Asia Pacific: SWOT Analysis
  • Fig. 66 Asia Pacific Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 67 Japan Key Country Dynamics
  • Fig. 68 Japan Target Disease Prevalence
  • Fig. 69 Japan Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 70 China Key Country Dynamics
  • Fig. 71 China Target Disease Prevalence
  • Fig. 72 China Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 73 India Key Country Dynamics
  • Fig. 74 India Target Disease Prevalence
  • Fig. 75 India Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 76 Australia Key Country Dynamics
  • Fig. 77 Australia Target Disease Prevalence
  • Fig. 78 Australia Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 79 South Korea Key Country Dynamics
  • Fig. 80 South Korea Target Disease Prevalence
  • Fig. 81 South Korea Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 82 Thailand Key Country Dynamics
  • Fig. 83 Thailand Target Disease Prevalence
  • Fig. 84 Thailand Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 85 Rest of APAC Erythropoietin Drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 86 Latin America (LATAM): SWOT Analysis
  • Fig. 87 Latin America Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 88 Brazil Key Country Dynamics
  • Fig. 89 Brazil Target Disease Prevalence
  • Fig. 90 Brazil Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 91 Mexico Key Country Dynamics
  • Fig. 92 Mexico Target Disease Prevalence
  • Fig. 93 Mexico Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 94 Argentina Key Country Dynamics
  • Fig. 95 Argentina Target Disease Prevalence
  • Fig. 96 Argentina Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 97 Rest of LATAM Erythropoietin Drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 98 Middle East & Africa (MEA): SWOT Analysis
  • Fig. 99 Middle East & Africa (MEA) Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 100 South Africa Key Country Dynamics
  • Fig. 101 Target Disease Prevalence
  • Fig. 102 South Africa Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 103 Saudi Arabia Key country dynamics
  • Fig. 104 Saudi Arabia Target Disease Prevalence
  • Fig. 105 Saudi Arabia Erythropoietin Drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 106 UAE Key Country Dynamics
  • Fig. 107 UAE Target Disease Prevalence
  • Fig. 108 UAE Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 109 Kuwait Key Country Dynamics
  • Fig. 110 Kuwait Target Disease Prevalence
  • Fig. 111 Kuwait Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 112 Rest of MEA Erythropoietin Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 113 Heat Map Analysis
  • Fig. 114 Strategic Framework